免疫系统与生物材料:不是敌人而是盟友

2016-04-26 科学公园 科学公园

各种各样的生物材料经常被植入人体以治疗疾病或者修复机体损伤。在设计和加工这些生物材料时,一个主要的原则是设法降低这些材料在植入体内后对免疫系统的刺激,然而一项新的研究却表明:适当的免疫系统反应反而有助于生物材料更好地发挥作用。 来自美国约翰·霍普金斯大学的研究人员首先在普通的实验用小鼠身上制造肌肉损伤,然后分别将几种生物材料植入受伤部位。观察表明,植入的生物材料显著地刺激了受伤部位周围的免

各种各样的生物材料经常被植入人体以治疗疾病或者修复机体损伤。在设计和加工这些生物材料时,一个主要的原则是设法降低这些材料在植入体内后对免疫系统的刺激,然而一项新的研究却表明:适当的免疫系统反应反而有助于生物材料更好地发挥作用。

来自美国约翰·霍普金斯大学的研究人员首先在普通的实验用小鼠身上制造肌肉损伤,然后分别将几种生物材料植入受伤部位。观察表明,植入的生物材料显著地刺激了受伤部位周围的免疫系统反应。接下来他们又在另一种经过基因工程改造的小鼠身上重复实验,这种小鼠体内缺乏成熟的B细胞和T细胞,这两种细胞在免疫反应中发挥着重要作用。实验表明,经过一段时间后,与对照组相比,这种小鼠受伤部位的修复程度明显较差,运动能力的恢复也明显不如对照组。

业内人士表示,这项研究的结果与此前我们的认识完全相反,表明看起来应该避免的免疫反应实际上能够帮助植入的生物材料更好地完成机体修复。这一研究不仅可以更好地指导生物材料的设计与合成,或许还可以启发研究者开发新的疗法。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
    2016-04-27 1de11f7fm56(暂无匿称)

    学习了一下新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
    2016-04-27 吴教授

    免疫排斥依然存在

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
    2016-04-27 老段

    对,亦敌亦友

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2076910, encodeId=67cd20e691059, content=<a href='/topic/show?id=dc626935e20' target=_blank style='color:#2F92EE;'>#生物材#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69357, encryptionId=dc626935e20, topicName=生物材)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Wed Aug 03 08:41:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502978, encodeId=8fb115029e84a, content=<a href='/topic/show?id=129069358ec' target=_blank style='color:#2F92EE;'>#生物材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69358, encryptionId=129069358ec, topicName=生物材料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89399597484, createdName=dongjia2013, createdTime=Thu Apr 28 05:41:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83044, encodeId=0d6983044bf, content=学习了一下新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Wed Apr 27 09:13:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=83032, encodeId=2ada8303214, content=免疫排斥依然存在, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170701/IMG595791009FB761316.jpg, createdBy=abd01695121, createdName=吴教授, createdTime=Wed Apr 27 07:41:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82986, encodeId=244d82986e8, content=对,亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Wed Apr 27 07:03:00 CST 2016, time=2016-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82940, encodeId=b4708294088, content=亦敌亦友, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a951716657, createdName=为何, createdTime=Tue Apr 26 22:30:00 CST 2016, time=2016-04-26, status=1, ipAttribution=)]
    2016-04-26 为何

    亦敌亦友

    0

相关资讯

Diabetes Care:人类胰岛移植完成III期临床 根治1型糖尿病已见曙光!

最新临床试验结果表明进行胰岛移植能够帮助1型糖尿病患者预防低血糖症,低血糖会导致病人出现痉挛,意识丧失,严重者甚至发生死亡,对生命造成威胁。研究人员发现这种治疗对于遭受过严重低血糖症的病人非常有效。   这项III期临床试验由美国国立卫生研究院NIAID和NIDDK两个研究所共同资助,同时该试验的设计也得到了美国FDA的认可,从一定程度上为纯化人类胰岛细胞的商品化应用提供了保证。

科学家尝试产前干细胞疗法拯救患病胎儿

他正准备开展针对受折磨胎儿的干细胞疗法临床试验,以期给他们一个更加健康的生命开端。 受一种骨病折磨的Oliver Semler希望,一种新的疗法能在胎儿出生前便将该疾病治愈。 图片来源:DAVID KLAMMER 当41年前Oliver Semler在德国出生时,他的一块骨头已经断裂。这块弓形的股骨和两天后的第二处骨折告诉医生,他患上了成骨不全症(OI)。这是一种会让

Science子刊:前列腺癌常规疗法可能影响免疫治疗效果促进复发

                                     根据美国西南医学中心,华南理工大学,中科院生物物理所等多个单位的研究人员共同发表的一项最新研究成果,前列腺癌病人和他们的医生在选择化

癌症免疫疗法的新贵:CD73

日前,Cell旗下《Trends in Cancer》发表了一篇题为“Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities”的综述。这一综述讨论了CD73与肿瘤发生、发展以及扩散之间的关系,强调了这一分子作为药物靶标的潜在价值,并表示CD73有望成为个性化癌症治疗中的新生物标志物。 近年来

Nat Immunol:γ干扰素有望成为真菌感染脓毒症的潜在治疗手段

《自然—免疫学》在线报道了有关脓毒症患者的免疫系统是如何发生故障的新发现。该研究展示了一种让免疫系统瘫痪发生逆转的新方法——免疫系统瘫痪是脓毒症的后期表现症状 脓毒症通常是由细菌或真菌进入血液引起,通常在就医时产生并且往往致命。在感染后数小时里,免疫细胞会变得极度活跃,通常在数天后,免疫系统发生瘫痪,患者将无法抵抗其他感染。但是,科学家一直未弄清,在脓毒症后期,免疫反应中的白细胞到底发挥了什

周杰伦的脊柱炎又严重了,这病真的治不好吗?

脊柱炎这个小妖精,竟然还敢折磨我们家杰伦!啥?还要折磨一辈子! 来源KK健康,转载请联系原作者Dr.K (zhongguokepu@163.com)